By proceeding, you agree to our Terms of Use and Privacy Policy.
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease.
25-27 January 2022
With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.
Event Ended
Virtual
Paid